- Home
- OPFI vs TIL Comparison
OPFI vs TIL Comparison
Compare OPFI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- TIL
- Stock Information
- Founded
- OPFI 2009
- TIL 2018
- Country
- OPFI United States
- TIL United States
- Employees
- OPFI N/A
- TIL N/A
- Industry
- OPFI Finance: Consumer Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- TIL Health Care
- Exchange
- OPFI Nasdaq
- TIL Nasdaq
- Market Cap
- OPFI 205.2M
- TIL 171.7M
- IPO Year
- OPFI N/A
- TIL 2021
- Fundamental
- Price
- OPFI $12.67
- TIL $26.95
- Analyst Decision
- OPFI Buy
- TIL Buy
- Analyst Count
- OPFI 2
- TIL 5
- Target Price
- OPFI $11.75
- TIL $119.00
- AVG Volume (30 Days)
- OPFI 1.2M
- TIL 316.4K
- Earning Date
- OPFI 05-07-2025
- TIL 05-13-2025
- Dividend Yield
- OPFI 1.97%
- TIL N/A
- EPS Growth
- OPFI N/A
- TIL N/A
- EPS
- OPFI N/A
- TIL N/A
- Revenue
- OPFI $305,566,000.00
- TIL N/A
- Revenue This Year
- OPFI $112.88
- TIL N/A
- Revenue Next Year
- OPFI $8.45
- TIL N/A
- P/E Ratio
- OPFI N/A
- TIL N/A
- Revenue Growth
- OPFI 31.46
- TIL N/A
- 52 Week Low
- OPFI $3.05
- TIL $9.62
- 52 Week High
- OPFI $17.73
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- OPFI 62.67
- TIL 65.08
- Support Level
- OPFI $11.16
- TIL $12.60
- Resistance Level
- OPFI $13.70
- TIL $35.28
- Average True Range (ATR)
- OPFI 0.70
- TIL 3.84
- MACD
- OPFI 0.06
- TIL 1.60
- Stochastic Oscillator
- OPFI 59.48
- TIL 63.27
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.